
|Articles|December 22, 2011
Dr. Susan Urba Discusses Cost Concerns for Treatment of Chemotherapy-Induced Nausea
Advertisement
In this segment, Dr. Susan Urba, University of Michigan, Comprehensive Cancer Center, talks about treatment guidelines and decisions relevant to chemotherapy-induced nausea and vomiting (CINV) in a managed care setting.
In addition, Dr. Urba warns of the consequences associated with the treatment of CINV when cost concerns impact best practices. Often, these consequences can include increased costs from uncontrolled symptoms and potential hospital admission due to dehydration.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO
2
GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale
3
GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis
4
Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss
5




